Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 110-114 , Summer 2008

Improving Cell Engraftment with Tissue Engineering

  • Erik J. Suuronen, BSc, PhD
    • ,
  • Drew Kuraitis, BSc
    • ,
  • Marc Ruel, MD, MPH

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Marc Ruel, MD, MPH, Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada, K1Y 4W7

References 

  1. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134:1540–1547
  2. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–997
  3. Patel AN, Genovese JA. Stem cell therapy for the treatment of heart failure. Curr Opin Cardiol. 2007;22:464–470
  4. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006;116:1865–1877
  5. Suuronen EJ, Price J, Veinot JP, et al. Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac function. J Thorac Cardiovasc Surg. 2007;134:1249–1258
  6. Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107:2134–2139
  7. Retuerto MA, Schalch P, Patejunas G, et al. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg. 2004;127:1041–1049discussion 1049-1051
  8. Zwaginga JJ, Doevendans P. Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repair and tissue engineering. Clin Exp Pharmacol Physiol. 2003;30:900–908
  9. Zisch AH, Lutolf MP, Hubbell JA. Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc Pathol. 2003;12:295–310
  10. Elcin YM, Dixit V, Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif Organs. 2001;25:558–565
  11. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg. 2002;124:28–34
  12. Ruel M, Wu GF, Khan TA, et al. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a swine endothelial dysfunction model. Circulation. 2003;108(suppl 1):II335–II340
  13. Zisch AH, Zeisberger SM, Ehrbar M, et al. Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2. Biomaterials. 2004;25:3245–3257
  14. Elcin YM, Dixit V, Gitnick G. Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis: in vitro and in vivo studies. Artif Cells Blood Substit Immobil Biotechnol. 1996;24:257–271
  15. Pieper JS, Hafmans T, van Wachem PB, et al. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res. 2002;62:185–194
  16. Tabata Y, Hijikata S, Muniruzzaman M, et al. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed. 1999;10:79–94
  17. Arras M, Mollnau H, Strasser R, et al. The delivery of angiogenic factors to the heart by microsphere therapy. Nat Biotechnol. 1998;16:159–162
  18. Jiang WG, Harding KG. Enhancement of wound tissue expansion and angiogenesis by matrix-embedded fibroblast (dermagraft), a role of hepatocyte growth factor/scatter factor. Int J Mol Med. 1998;2:203–210
  19. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release. 2004;94:187–193
  20. Liu J, Hu Q, Wang Z, et al. Autologous stem cell transplantation for myocardial repair. Am J Physiol Heart Circ Physiol. 2004;287:H501–H511
  21. Kellar RS, Shepherd BR, Larson DF, et al. Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng. 2005;11:1678–1687
  22. Cortes-Morichetti M, Frati G, Schussler O, et al. Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regeneration. Tissue Eng. 2007;13:2681–2687
  23. Robinson KA, Li J, Mathison M, et al. Extracellular matrix scaffold for cardiac repair. Circulation. 2005;112:I135–I143
  24. Kofidis T, Lebl DR, Martinez EC, et al. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation. 2005;112:I173–I177
  25. Christman KL, Vardanian AJ, Fang Q, et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44:654–660
  26. Zhang P, Zhang H, Wang H, et al. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs. 2006;30:86–93
  27. Caulfield JB, Borg TK. The collagen network of the heart. Lab Invest. 1979;40:364–372
  28. Badylak SF. Modification of natural polymers: Collagen, in Methods of Tissue Engineering. In: San Diego, CA: Academic Press; 2002;p. 505–514
  29. Suuronen EJ, Veinot JP, Wong S, et al. Tissue-engineered injectable collagen-based matrices for improved cell delivery and vascularization of ischemic tissue using CD133+ progenitors expanded from the peripheral blood. Circulation. 2006;114:I138–I144
  30. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282:1–18
  31. Chan BP, Hui TY, Yeung CW, et al. Self-assembled collagen-human mesenchymal stem cell microspheres for regenerative medicine. Biomaterials. 2007;28:4652–4666
  32. Batorsky A, Liao J, Lund AW, et al. Encapsulation of adult human mesenchymal stem cells within collagen-agarose microenvironments. Biotechnol Bioeng. 2005;92:492–500
  33. Ferreira LS, Gerecht S, Fuller J, et al. Bioactive hydrogel scaffolds for controllable vascular differentiation of human embryonic stem cells. Biomaterials. 2007;28:2706–2717
  34. Zhang WJ, Liu W, Cui L, et al. Tissue engineering of blood vessel. J Cell Mol Med. 2007;11:945–957
  35. Ucuzian AA, Greisler HP. In vitro models of angiogenesis. World J Surg. 2007;31:654–663
  36. Loffek S, Zigrino P, Steiger J, et al. Melanoma cell-derived vascular endothelial growth factor induces endothelial tubulogenesis within fibrin gels by a metalloproteinase-mediated mechanism. Eur J Cell Biol. 2006;85:1167–1177
  37. Sreerekha PR, Divya P, Krishnan LK. Adult stem cell homing and differentiation in vitro on composite fibrin matrix. Cell Prolif. 2006;39:301–312
  38. Ishikawa T, Eguchi M, Wada M, et al. Establishment of a functionally active collagen-binding vascular endothelial growth factor fusion protein in situ. Arterioscler Thromb Vasc Biol. 2006;26:1998–2004
  39. Rehman J, Li J, Orschell CM, et al. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164–1169
  40. Stellos K, Langer H, Daub K, et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation. 2008;117:206–215
  41. Jin H, Aiyer A, Su J, et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest. 2006;116:652–662
  42. Langer H, May AE, Daub K, et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ Res. 2006;98:e2–e10
  43. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14:213–221

 This work was supported by the Canadian Institutes of Health Research, grant MOP-77536 (to MR and EJS) and the Heart and Stroke Foundation of Ontario, grant NA5905 (to MR).

PII: S1043-0679(08)00060-9

doi: 10.1053/j.semtcvs.2008.03.005

Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 110-114 , Summer 2008

Article Tools

* Image Usage & Resolution